FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN RENEEICIAL	OWNERSH

ONB APPROVAL								
OMB Number: 3235-02								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						,			1 7 -									
1. Name and Address of Reporting Person*  DEMAREE JOHN				2. Issuer Name <b>and</b> Ticker or Trading Symbol G1 Therapeutics, Inc. GTHX						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)								
<u>DEMA</u>	REE JUF	<u>11N</u>				<u>rerupee</u>	rerec	<u>, mer</u> [ 0					Director			10% Ow	ner	
(Loot)	/_	irot\	(Middle)									X	Officer (below)	give title		Other (s below)	pecify	
(Last)	`	irst)	(Middle)	3.	Date o	of Earliest	Trans	saction (Mont	h/Dav/Year)			1	Chief Commercial Officer					
C/O G1 THERAPEUTICS, 79 TW ALEXANDER DR.				3. Date of Earliest Transaction (Month/Day/Year) 07/03/2018														
4501 RE	SEARCH C	COMMONS, SU	ITE 100															
(Street)			4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Individual or Joint/Group Filing (Check Applicable Line)									
RESEAF	RCH											X	Form fil	ed by One	Repo	rting Person		
TRIANG PARK	GLE N	С	27709						Form filed by More than One Reporting Person									
(City)	(S	tate)	(Zip)															
		Ta	ble I - Non-I	Derivati	ve Se	curities	s Ac	quired, D	isposed	of, or E	Benefi	cially	Owned					
Date				. Transactio Date Month/Day/	Execution Date,		Code (Instr.		1 and 5) Securities Beneficial Owned Fo		Form (D) o		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership				
			Code	Amount			(A)	) or F	Price	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative   Conversion   Da		(Month/Day/Year)   if any	Execution Date	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	or Nun	ount nber hares		Transaction(s) (Instr. 4)				
Stock Option (right to buy)	\$45.5	07/03/2018		A		225,000		(1)	07/03/2028	Commo		5,000	\$0.00	225,0	00	D		

## **Explanation of Responses:**

1. The shares underlying this option vest as to 25% of the shares on July 3, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.

## Remarks:

Megan Gates, attorney-in-fact 07/06/2018

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.